Background: Carbapenem-resistant Enterobacteriaceae (CRE) are an important cause of infections in cancer patients. The proportion of carbapenem resistance and the types of carbapenemase-encoding genes in Enterobacteriaceae isolated from cancer patients were determined in this study.
Methodology: Bacteria isolated from adult, in-ward cancer patients with lower respiratory tract infections (LRTI), skin and soft tissue infections (SSTI), or urinary tract infections (UTI) were included in the study. Enterobacteriaceae were identified up to the species level by API® 20E test kits. Carbapenem resistance was defined as non-susceptibility to either imipenem or meropenem in the disc diffusion test. Major carbapenemase-encoding genes (blaKPC, blaNDM, blaOXA-48, blaIMP, and blaVIM) were detected by the GeneXpert® Carba-R real-time PCR instrument.
Results: Enterobacteriaceae comprised 57% (94/165) of the bacterial isolates. Carbapenem resistance among Enterobacteriaceae was 46.8% (44/94). Klebsiella pneumoniae (65.9%, 29/44) was the predominant CRE isolate followed by Escherichia coli (25%, 11/44). The majority of CRE isolates (72.7%, 32/44) had a meropenem MIC of ≥ 32 µg/mL. Carbapenemase-encoding genes were identified in 43 of the 44 CRE isolates. blaNDM was the most prevalent carbapenemase-encoding gene and was detected in 67.4% (29/43) of Enterobacteriaceae isolates. No isolate was positive for blaIMP. Sixteen (37.2%) isolates co-harbored more than one carbapenemase-encoding gene. Two Enterobacteriaceae isolates were found to harbor blaVIM.
Conclusions: Nearly all CRE isolated in this study were carbapenemase producers. This study documented the emergence of blaVIM harboring Enterobacteriaceae for the first time in Sri Lanka.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3855/jidc.19499 | DOI Listing |
Cancer Treat Rev
December 2024
SOLTI Cancer Research Group, Barcelona, Spain; Statistics Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Electronic address:
Introduction: Antibody-drug conjugates (ADCs) trastuzumab-deruxtecan (T-DXd) and sacituzumab-govitecan (SG) provided significant progression-free survival (PFS) and overall survival (OS) improvements over chemotherapy (CT) in pretreated hormone receptor-positive (HR+) and triple-negative (TN)/HER2-low metastatic breast cancer (MBC). However, no direct comparison between the two exists, nor with the more recent datopotamab-deruxtecan (Dato-DXd).
Methods: We conducted a network meta-analysis (NMA) to compare efficacy and safety of T-DXd and SG in CT-pretreated HR+ and TN/HER2-low MBC and assess their benefit over standard CT, exploring also a comparison with Dato-DXd.
Lung Cancer
December 2024
State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic address:
Background: Primary pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare subtype of non-small-cell lung cancer. This study aims to compare the efficacy and safety of perioperative PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone in stage II-IIIB PLELC patients.
Patients And Methods: This retrospective study included stage II-IIIB PLELC patients.
Lung Cancer
December 2024
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Background: The upfront treatment of non-oncogene-addicted NSCLC relies on immunotherapy alone (ICI) or in combination with chemotherapy (CT-ICI). Genomic aberrations such as KRAS, TP53, KEAP1, SMARCA4, or STK11 may impact survival outcomes.
Methods: We performed an observational study of 145 patients treated with first-line IO or CT-ICI for advanced non-squamous (nsq) NSCLC at our institution tested with an extensive lab-developed NGS panel.
Leuk Lymphoma
December 2024
Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.
Clin Transl Oncol
December 2024
Dr Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Health Sciences University, Ankara, Turkey.
Background: In triple-negative breast cancer (TNBC) patients receiving adjuvant capecitabine, the impact of HER2 expression on survival outcomes is unclear.
Methods: Between June 2017 and December 2023, 112 patients with TNBC who received adjuvant capecitabine due to residual masses after neoadjuvant chemotherapy (NACT) in three hospitals were identified. HER2 is analyzed through immunohistochemistry (IHC) and/or in situ hybridization in the core biopsy and/or post-surgical histopathologies.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!